Pentoxifylline (PTXF), an FDA-approved drug, can cause selective degradation of c-Rel, without affecting p65.PTXF has been widely used in the therapy of type 2 diabetes mellitus and chronic kidney disease (CKD). The gene discussed is RELA; the disease is type 2 diabetes mellitus.